-
Article
Open AccessNanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy
-
Article
Open AccessNeutralizing antibodies against SARS-CoV-2 virus after vaccination in patients with neurofibromatosis type 1
-
Article
Open AccessPreventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2
Effective drugs with broad spectrum safety profile to all people are highly expected to combat COVID-19 caused by SARS-CoV-2. Here we report that nelfinavir, an FDA approved drug for the treatment of HIV infec...
-
Article
Open AccessCD147 receptor is essential for TFF3-mediated signaling regulating colorectal cancer progression
Major gaps in understanding the molecular mechanisms of colorectal cancer (CRC) progression and intestinal mucosal repair have hampered therapeutic development for gastrointestinal disorders. Trefoil factor 3 ...
-
Article
Open AccessSafety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial
Recent evidence suggests that CD147 serves as a novel receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Blocking CD147 via anti-CD147 antibody could suppress the in vitro SAR...
-
Article
Open AccessCD147-spike protein is a novel route for SARS-CoV-2 infection to host cells
In face of the everlasting battle toward COVID-19 and the rapid evolution of SARS-CoV-2, no specific and effective drugs for treating this disease have been reported until today. Angiotensin-converting enzyme ...